Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks, a clinical-stage biotechnology company focusing on novel biotherapeutics for difficult-to-treat diseases, has announced its participation in several upcoming investor conferences.
Management will engage in one-on-one meetings and presentations at these events:
1. Jefferies Global Healthcare Conference: June 5-6, with a fireside chat on June 5 at 10:30 am ET in New York.
2. Goldman Sachs 45th Annual Global Healthcare Conference: June 12 at 2:00 pm ET in Miami.
3. Citi’s 2024 European Healthcare Conference: Virtual one-on-one meetings on June 20.
- Zymeworks' participation in high-profile investor conferences can increase visibility and attract potential investors.
- Engagement in these events demonstrates proactive management and willingness to communicate with stakeholders.
- The diverse dates and locations of the conferences provide multiple opportunities to connect with a wide range of investors.
- No new clinical or financial data were disclosed in the announcement, possibly indicating a lack of immediate positive developments.
- The announcement did not address any ongoing challenges or risks the company might be facing.
VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences:
- Jefferies Global Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings on June 5-6 and a fireside chat on June 5 at 10:30 am Eastern Time (ET) in New York, NY.
- Goldman Sachs 45th Annual Global Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings and present on June 12 at 2:00 pm ET in Miami, FL.
- Citi’s 2024 European Healthcare Conference: Zymeworks’ management will participate in virtual one-on-one meetings on June 20.
About Zymeworks Inc.
Zymeworks is a global biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat cancers and other diseases. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with HER2-expressing cancers. A Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for the HER2-targeted bispecific antibody zanidatamab as a treatment for previously-treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC) has been submitted. If approved, zanidatamab would be the first HER2-targeted treatment specifically approved for BTC in the U.S. Zymeworks is rapidly advancing a deep pipeline of product candidates based on its experience and capabilities in both antibody-drug conjugates and multispecific antibody therapeutics across multiple novel targets in indications that represent areas of significant unmet medical need. In addition to Zymeworks’ wholly owned pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.
Contacts:
Investor Inquiries:
Shrinal Inamdar
Director, Investor Relations
(604) 678-1388
ir@zymeworks.com
Media Inquiries:
Diana Papove
Senior Director, Corporate Communications
(604) 678-1388
media@zymeworks.com
FAQ
When will Zymeworks participate in the Jefferies Global Healthcare Conference?
What is the date and time of Zymeworks' presentation at the Goldman Sachs 45th Annual Global Healthcare Conference?
Will Zymeworks participate in virtual meetings during any of the conferences?
What is the stock symbol for Zymeworks?
